Outcomes of COVID-19 vaccination in 323 patients with clonal and non-clonal mast cell activation disorders.
作者信息
Giannetti Matthew P, Olivieri Francesco, Godwin Grace, Weller Emma, Nicoloro-SantaBarbara Jennifer, Bonadonna Patrizia, Zanotti Roberta, Zanoni Giovanna, Hartmann Karin, Castells Mariana
机构信息
Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Harvard Medical School, Boston, Massachusetts, USA.
出版信息
Allergy. 2023 Jan;78(1):301-304. doi: 10.1111/all.15476. Epub 2022 Aug 23.
Abstract
摘要
相似文献
1
Outcomes of COVID-19 vaccination in 323 patients with clonal and non-clonal mast cell activation disorders.
Allergy. 2023 Jan;78(1):301-304. doi: 10.1111/all.15476. Epub 2022 Aug 23.
2
Safety of COVID-19 vaccination in patients with clonal mast cell disorders.
J Allergy Clin Immunol Pract. 2022 May;10(5):1374-1376.e3. doi: 10.1016/j.jaip.2022.01.030. Epub 2022 Feb 1.
3
Safety of COVID-19 vaccination in patients with mastocytosis and monoclonal mast cell activation syndrome.
J Allergy Clin Immunol Pract. 2021 Aug;9(8):3198-3199. doi: 10.1016/j.jaip.2021.05.010. Epub 2021 May 24.
4
How to evaluate the patient with a suspected mast cell disorder and how/when to manage symptoms.
Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):55-63. doi: 10.1182/hematology.2022000366.
5
Delving Into COVID-19 Vaccination-Induced Anaphylaxis: Are mRNA Vaccines Safe in Mast Cell Disorders?
J Investig Allergol Clin Immunol. 2021 Apr 20;31(2):193-195. doi: 10.18176/jiaci.0680. Epub 2021 Feb 12.
6
COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM).
J Allergy Clin Immunol Pract. 2021 Jun;9(6):2139-2144. doi: 10.1016/j.jaip.2021.03.041. Epub 2021 Apr 5.
7
Effective Anti-SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders.
J Allergy Clin Immunol Pract. 2022 May;10(5):1356-1364.e2. doi: 10.1016/j.jaip.2021.12.038. Epub 2022 Jan 21.
8
SARS-CoV-2 vaccination complicated by small fiber neuropathy, mast cell activation syndrome, and pericarditis.
Clinics (Sao Paulo). 2023 Nov 11;78:100304. doi: 10.1016/j.clinsp.2023.100304. eCollection 2023.
9
Clinical Approach to Mast Cell Activation Syndrome: A Practical Overview.
J Investig Allergol Clin Immunol. 2021 Dec 21;31(6):461-470. doi: 10.18176/jiaci.0675. Epub 2020 Feb 5.
10
mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis.
J Allergy Clin Immunol. 2021 Mar;147(3):877-878. doi: 10.1016/j.jaci.2021.01.004. Epub 2021 Jan 19.
引用本文的文献
1
COVID-19 mRNA-1273 vaccination induced mast cell activation with strongly elevated Th cytokines in a systemic mastocytosis patient.
Inflamm Res. 2025 Apr 29;74(1):71. doi: 10.1007/s00011-025-02032-5.
2
Safety and Tolerability of COVID-19 Vaccine in Mast Cell Disorders Real-Life Data from a Single Centre in Italy.
Vaccines (Basel). 2024 Feb 16;12(2):202. doi: 10.3390/vaccines12020202.
3
Challenges in Drug and Hymenoptera Venom Hypersensitivity Diagnosis and Management in Mastocytosis.
Diagnostics (Basel). 2024 Jan 5;14(2):123. doi: 10.3390/diagnostics14020123.
4
Safety of COVID-19 mRNA vaccination and effects of SARS-CoV-2 infection in children and adults with mast cell disorders.
Clin Exp Med. 2023 Dec;23(8):4937-4942. doi: 10.1007/s10238-023-01213-y. Epub 2023 Oct 14.
5
Non-steroidal anti-inflammatory drug-induced anaphylaxis infrequent in 388 patients with mastocytosis: A two-center retrospective cohort study.
Front Allergy. 2022 Dec 5;3:1071807. doi: 10.3389/falgy.2022.1071807. eCollection 2022.
Zotero 插件